Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-B7H7 monoclonal antibody HBM1020

A recombinant human monoclonal antibody directed against HERV-H LTR-associating protein 2 (HHLA2; B7 homolog 7; B7H7), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-B7H7 monoclonal antibody HBM1020 binds to B7H7 and blocks the interaction between B7H7 and its receptors. This abrogates the B7H7-mediated inhibition of T-cell and nature killer (NK) cell activation, which may lead to enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response and NK cell cytotoxicity against cancer cells. B7H7, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and a negative regulator of T-cell and NK-cell activation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-HHLA2 monoclonal antibody HBM1020
Code name:HBM 1020
HBM-1020
HBM1020
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search